Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events

References

• RogerVLGoASLloyd-JonesDMAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2012 update: a report from the American Heart AssociationCirculation20121251e2e22022179539
   PubMed Web of Science ®Google Scholar
• HennekensCHAspirin in the treatment and prevention of cardiovascular disease: current perspective and future directionsCurr Atheroscler Rep20079540941618001625
   PubMedGoogle Scholar
• BaigentCBlackwellLCollinsRAntithrombotic Trialists’ (ATT) CollaborationAspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trialsLancet200937396781849186019482214
   PubMed Web of Science ®Google Scholar
• BergerJSLalaAKrantzMJBakerGSHiattWRAspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trialAm Heart J2011162111512421742097
   PubMed Web of Science ®Google Scholar
• SeshasaiSRWijesuriyaSSivakumaranREffect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trialsArch Intern Med2012172320921622231610
   PubMed Web of Science ®Google Scholar
• SussmanJBVijanSChoiHHaywardRAIndividual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelinesCir Cardiovasc Qual Outcomes201143268275
   PubMed Web of Science ®Google Scholar
• ShiotaniAManabeNKamadaTFujimuraYSakakibaraHarumaKRisk and prevention factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive reviewJ Gastroenterol Hepatol201227Suppl 381222486865
   PubMedGoogle Scholar
• AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusionsEur Heart J200728161925192717604291
   PubMed Web of Science ®Google Scholar
• PearsonTABlairSNDanielsSRAHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating CommitteeCirculation2002106338839112119259
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task ForceAspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statementAnn Intern Med2009150639640419293072
   PubMed Web of Science ®Google Scholar
• PignoneMAlbertsMJColwellJAAmerican Diabetes AssociationAmerican Heart AssociationAmerican College of Cardiology FoundationAspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology FoundationDiabetes Care20103361395140220508233
   PubMed Web of Science ®Google Scholar
• PignoneMWilliamsCDAspirin for primary prevention of cardiovascular disease in diabetes mellitusNat Rev Endocrinol201061161962820856266
   PubMed Web of Science ®Google Scholar
• ChenWHChengXLeePYAspirin resistance and adverse clinical events in patients with coronary artery diseaseAm J Med2007120763163517602938
   PubMed Web of Science ®Google Scholar
• KrasopoulosGBristerSJBeattieWSBuchananMRAspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ2008336763719519818202034
   PubMed Web of Science ®Google Scholar
• Biondi-ZoccaiGGLotrionteMAgostoniPA systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery diseaseEur Heart J200627222667267417053008
   PubMed Web of Science ®Google Scholar
• KulkarniSPAlexanderKPLytleBHeissGPetersonEDLong-term adherence with cardiovascular drug regimensAm Heart J2006151118519116368315
   PubMed Web of Science ®Google Scholar
• PrattSThompsonVJElkinEPNæsdalJSörstadiumEThe impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular riskAm J Cardiovasc Drugs201010528128820666569
   PubMed Web of Science ®Google Scholar
• LanasAScheimanJLow-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatmentCurr Med Res Opin200723116317317257477
   PubMed Web of Science ®Google Scholar
• FihnSDGardinJMAbramsJAmerican College of Cardiology Foundation2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic SurgeonsCirculation2012126253097313723166210
   PubMed Web of Science ®Google Scholar
• LaiKCLamSKChuKMLansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin useN Engl J Med2002346262033203812087138
   PubMed Web of Science ®Google Scholar
• ChanFKChungSCSuenBYPreventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxenN Engl J Med20013441396797311274623
   PubMed Web of Science ®Google Scholar
• NgFHTunggalPChuWMEsomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarctionAm J Gastroenterol2012107338939622108447
   PubMed Web of Science ®Google Scholar
• LaineLApproaches to nonsteroidal anti-inflammatory drug use in the high-risk patientGastroenterology2001120359460611179238
   PubMed Web of Science ®Google Scholar
• ChanFKChingJYHungLCClopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleedingN Engl J Med2005352323824415659723
   PubMed Web of Science ®Google Scholar
• ZhuLLXuLCChenYZhouQZengSPoor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medicationsWorld J Gastroenterol201218243167317222791953
   PubMed Web of Science ®Google Scholar
• The pharmaletter [homepage on the Internet]AstraZeneca gets EU approval for Axanum; Merck and Co files ridaforolimus with EMAThe pharmaletter2011 Available from: http://www.thepharmaletter.com/file/106266/astrazeneca-gets-eu-approval-for-axanum-merck-co-files-ridaforolimus-with-ema.htmlAccessed December 17, 2012
   Google Scholar
• NiaziMAnderssonTNauclérESundinMNaesdalJEvaluation of the pharmacokinetic interaction between esomprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteersInt J Clin Pharmacol Ther200947956456919761715
   PubMed Web of Science ®Google Scholar
• NiaziMAnderssonTNauclérENæsdalJEvaluation of bioequivalence between a single-capsule formulation of esomprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given seperately in healthy volunteersInt J Clin Pharmacol Ther201149216917621255534
   PubMed Web of Science ®Google Scholar
• NefesogluFZAyanoglu-DülgerGUlusoyNBImeryüzNInteraction of omeprazole with enteric-coated salicylate tabletsInt J Clin Pharmacol Ther199836105495539799060
   PubMed Web of Science ®Google Scholar
• CharlotMGroveELHansenPRProton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched studyBMJ2011342d269021562004
   PubMed Web of Science ®Google Scholar
• WurtzMGroveELKristensenSDHvasAMThe antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery diseaseHeart201096536837119910291
   PubMed Web of Science ®Google Scholar
• AdamopoulosABSakizlisGNNasothimiouEGDo proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover studyJ Cardiovasc Pharmacol200954216316819568178
   PubMed Web of Science ®Google Scholar
• AnderssonTMorrisonDNagyPPisupatiJSchettlerJWarnerTDEvaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in health volunteersAm J Cardiovasc Drugs201212421722422631032
   PubMed Web of Science ®Google Scholar
• YeomansNLanasALabenzJEfficacy of esomeprazole (20 mg once daily) for reducing the risk of gastrointestinal ulcers associated with continuous use of low-dose aspirinAm J Gastroenterol2008103102465247318637091
   PubMed Web of Science ®Google Scholar
• ScheimanJMDevereauxPJHerlitzJPrevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomized, controlled trial (OBERON)Heart2011971079780221415072
   PubMed Web of Science ®Google Scholar
• YangYXLewisJDEpsteinSMetzDCLong-term proton pump inhibitor therapy and risk of hip fractureJAMA2006296242947295317190895
   PubMed Web of Science ®Google Scholar
• GraySLLaCroixAZLarsonJProton pump inhibitor use, hip fracture and change in bone mineral density in postmenopausal women: results from the Women’s Health InitiativeArch Intern Med2010170976577120458083
   PubMedGoogle Scholar
• RouxCBriotKGossecLIncrease in vertebral fracture risk in postmenopausal women using omeprazoleCalcif Tissue Int2009841131919023510
   PubMed Web of Science ®Google Scholar
• KhaliliHHuangESJacobsonBCCamargoCAJrFeskanichDChanATUse of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort studyBMJ2012344e37222294756
   PubMed Web of Science ®Google Scholar
• YuEWBauerSRBainPABauerDCProton pump inhibitors and risk of fractures: a meta-analysis of 11 international studiesAm J Med2011124651952621605729
   PubMed Web of Science ®Google Scholar
• AseeriMSchroederTKramerJZackulaRGastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patientsAm J Gastroenterol200810392308231318702653
   PubMed Web of Science ®Google Scholar
• LooVGBourgaultAMPoirierLHost and pathogen factors for Clostridium difficile infection and colonizationN Engl J Med2011365181693170322047560
   PubMed Web of Science ®Google Scholar
• MadanickRDProton pump inhibitor side effects and drug interactions: much ado about nothing?Cleve Clin J Med2011781394921199906
   PubMed Web of Science ®Google Scholar
• AliTRobertsDNTierneyWMLong-term safety concerns with proton pump inhibitorsAm J Med20091221089690319786155
   PubMed Web of Science ®Google Scholar
• ChapmanDBReesCJLippertDSataloffRTWrightSCJrAdverse effects of long-term proton pump inhibitor use: a review for the otolaryngologistJ Voice201125223624020144536
   PubMed Web of Science ®Google Scholar
• AnderssonTHassan-AlinMHasselgrenGRöhssKDrug interaction studies with esomeprazole, the (S)-isomer of omeprazoleClin Pharmacokinet200140752353711510629
   PubMed Web of Science ®Google Scholar
• O’DonoghueMLBraunwaldEAntmanEMPharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with and without a proton pump inhibitor: an analysis of two randomized trialsLancet2009374969498999719726078
   PubMed Web of Science ®Google Scholar
• BhattDLCryerBLConstantCFCOGENT InvestigatorsClopidogrel with or without omeprazole in coronary artery diseaseN Engl J Med2010363201909191720925534
   PubMed Web of Science ®Google Scholar
• HoPMMaddoxTMWangLRisk of adverse outcomes associated with comcomitant use of clopidogrel and proton pump inhibitors following acute coronary syndromeJAMA2009301993794419258584
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [homepage on the Internet]Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC)Silver SpringUS Food and Drug Administration2009 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htmAccessed February 2, 2013
   Google Scholar
• FocksJJBrouwerMAvan OijenMGLanasABhattDLVerheugtFWConcomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcomes-a systematic reviewHeart201399852052722851683
   PubMed Web of Science ®Google Scholar
• AstraZeneca PharmaceuticalsEsomeprazole (Nexium) US Prescribing InformationWilmingtonAstraZeneca Pharmaceuticals LP2012 Available from: http://www1.astrazeneca-us.com/pi/Nexium.pdfAccessed February 3, 2013
   Google Scholar
• EarnshawSRScheimanJFendrickAMMcDadeCPignoneMCost-utility of aspirin and proton pump inhibitors for primary preventionArch Intern Med2011171321822521325111
   PubMedGoogle Scholar
• SainiSDSchoenfeldPFendrickAMScheimanJCost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular preventionArch Intern Med2008168151684169018695083
   PubMedGoogle Scholar
• SainiSDFendrickAMScheimanJMCost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary preventionAliment Pharmacol Ther201134224325121615437
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2011Diabetes Care201134Suppl 1S11S6121193625
   PubMed Web of Science ®Google Scholar